US lawmakers revive stalled inquiry into copycat collusion

14 August 2019
congress_senate_house_hearing_committee_enquiry_big

Long-time US healthcare reform advocates Elijah Cummings and Bernie Sanders have written letters to several drugmakers in an effort to breathe new life into a 2014 investigation into generic price fixing.

Congressman Cummings, Chair of the House Oversight Committee, and Senator Sanders, a presidential candidate and advocate of “Medicare for all,” have demanded answers from Teva Pharmaceutical (NYSE: TEVA), Mylan (Nasdaq: MYL) and Heritage Pharmaceuticals.

The letters are aimed at renewing a probe into alleged price coordination, which saw the prices of some pharmaceutical products rise by over 8,000% between October 2013 and April 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics